Valeant, Actavis, Mylan Rumored to Eye Pfizer Generics Unit

Jan 14, 2014

Reuters

According to an exclusive report from Reuters, drugmakers Valeant Pharmaceuticals International Inc, Actavis Plc and Mylan Inc have all expressed interest in buying Pfizer Inc's branded generics business, but no active discussions are going on at this time, according to three people close to the matter.

As of January 1, Pfizer officially divided into three separate business units. The current unit of interest is Pfizer's "value" products business, which consists of off-patent products and products soon-to-be off patent.

The deal has the potential to catapult a buyer into the ranks of the biggest pharmaceutical companies in the world.

Read the Reuters press release



Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments